Triplet Therapeutics to Present at Upcoming Events – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Triplet Therapeutics, Inc., a biotechnology company leveraging insights from the human genetics of repeat expansion disorders (REDs), today announced that Nessan Bermingham, Ph.D., Triplets chief executive officer, president and founder, will present at the following upcoming virtual events:

Dr. Bermingham will discuss Triplets recent activities, including plans to file an investigational new drug application for TTX-3360 in Huntingtons disease in the second half of 2021, pipeline development and completion of enrollment of SHIELD HD, its natural history study of Huntingtons disease.

About Triplet TherapeuticsTriplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) a group of more than 50 known genetic diseases including Huntingtons disease (HD), myotonic dystrophy type 1 (DM1), spinocerebellar ataxias (SCAs), fragile X syndrome and familial amyotrophic lateral sclerosis (ALS) leveraging insights from patient genetics. Triplet uses a proprietary approach to design, develop and deliver potential therapeutics for REDs, enabling the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs.

Triplet is headquartered in Cambridge, Mass. For more information, please visit http://www.triplettx.com.

About TTX-3360TTX-3360, an antisense oligonucleotide, is Triplets first clinical candidate. TTX-3360 is the first clinical candidate with the potential to modify the course of REDs, including HD, by targeting the DDR pathway. Triplet plans to file an investigational new drug application for TTX-3360 in the second half of 2021, with a focus on HD. TTX-3360 may also be a candidate for the treatment of other central nervous system diseases including SCAs, DM1 and approximately 30 additional potential REDs impacting the central nervous system.

Follow this link:
Triplet Therapeutics to Present at Upcoming Events - Business Wire